Sunshine Nuohe Plans to Acquire Part of Biling Bio's Equity for 10 Million Yuan

财中社··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Sunshine Nuohe plans to acquire 40,900 yuan of registered capital in Shanghai Biling Biotechnology from Hangzhou Jiaozi Tea for 10 million yuan in cash. After the transaction, the company's stake in Biling Bio will increase from 2.0435 percent to 2.2671 percent. In the most recent year, Biling Bio had total assets of 316 million yuan, net assets of 314 million yuan, revenue of 103,900 yuan, and a loss of about 47.89 million yuan. The company said the deal will support its overall strategic layout in novel nano-conjugated drugs and precision nano-delivery, enhancing competitiveness in the pharmaceutical industry. In the first quarter of 2026, Sunshine Nuohe posted revenue of 197 million yuan and net profit attributable to the parent of 20.63 million yuan.

Impact on assets 1

Others▲

Off-coverage companies 2

上海弼领生物技术有限公司i
Private▲ PositiveCapitalrelevance

Biling Bio receives a cash injection and increased valuation from the acquisition, though it is currently loss-making.

杭州交子茶业有限公司i
Private▲ PositiveCapitalrelevance

Hangzhou Jiaozi Tea sells part of its stake in Biling Bio for 10 million yuan, realizing a return.